Nanobiotix S.A.

ENXTPA:NANO Stock Report

Market Cap: €139.4m

Nanobiotix Management

Management criteria checks 1/4

Nanobiotix's CEO is Laurent Levy, appointed in Mar 2003, has a tenure of 21.75 years. total yearly compensation is €3.40M, comprised of 12.1% salary and 87.9% bonuses, including company stock and options. directly owns 2.4% of the company’s shares, worth €3.35M. The average tenure of the management team and the board of directors is 5.4 years and 2.1 years respectively.

Key information

Laurent Levy

Chief executive officer

€3.4m

Total compensation

CEO salary percentage12.1%
CEO tenure21.8yrs
CEO ownership2.4%
Management average tenure5.4yrs
Board average tenure2.1yrs

Recent management updates

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

Dec 22
How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

Recent updates

Some Confidence Is Lacking In Nanobiotix S.A. (EPA:NANO) As Shares Slide 26%

Nov 28
Some Confidence Is Lacking In Nanobiotix S.A. (EPA:NANO) As Shares Slide 26%

Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 29
Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

May 14
Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

Apr 26
We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

May 11
Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Dec 06
Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Is Nanobiotix (EPA:NANO) Using Too Much Debt?

Jun 04
Is Nanobiotix (EPA:NANO) Using Too Much Debt?

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

Dec 22
How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

CEO Compensation Analysis

How has Laurent Levy's remuneration changed compared to Nanobiotix's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-€33m

Mar 31 2024n/an/a

-€37m

Dec 31 2023€3m€411k

-€40m

Sep 30 2023n/an/a

-€49m

Jun 30 2023n/an/a

-€59m

Mar 31 2023n/an/a

-€58m

Dec 31 2022€1m€380k

-€57m

Sep 30 2022n/an/a

-€50m

Jun 30 2022n/an/a

-€43m

Mar 31 2022n/an/a

-€45m

Dec 31 2021€4m€380k

-€47m

Sep 30 2021n/an/a

-€45m

Jun 30 2021n/an/a

-€43m

Mar 31 2021n/an/a

-€39m

Dec 31 2020€818k€330k

-€34m

Sep 30 2020n/an/a

-€41m

Jun 30 2020n/an/a

-€48m

Mar 31 2020n/an/a

-€49m

Dec 31 2019€2m€330k

-€51m

Sep 30 2019n/an/a

-€46m

Jun 30 2019n/an/a

-€42m

Mar 31 2019n/an/a

-€36m

Dec 31 2018€1m€300k

-€30m

Sep 30 2018n/an/a

-€28m

Jun 30 2018n/an/a

-€27m

Mar 31 2018n/an/a

-€26m

Dec 31 2017€861k€253k

-€26m

Compensation vs Market: Laurent's total compensation ($USD3.53M) is above average for companies of similar size in the French market ($USD310.29K).

Compensation vs Earnings: Laurent's compensation has increased whilst the company is unprofitable.

CEO

Laurent Levy (51 yo)

21.8yrs

Tenure

€3,396,084

Compensation

Mr. Laurent Lévy, Ph.D. has been the President of the Executive Board at Nanobiotix S.A. since May 27, 2004 and its Chief Executive Officer since March 2003. Mr. Lévy has a thorough understanding of the te...

Leadership Team

NamePositionTenureCompensationOwnership
Laurent Levy
Co-Founder21.8yrs€3.40m2.4%
€ 3.3m
Bart Van Rhijn
Chief Financial & Business Officer and Member of Executive Board3.5yrs€1.50m0%
€ 0
Anne-Juliette Hermant
Chief People Officer & Member of Executive Board5.4yrs€801.96k0.30%
€ 411.6k
Louis Kayitalire
Chief Medical Officer1.3yrs€500.80kno data
Earl Bergey
Co-Founder21.9yrsno datano data
Craig West
Senior Vice President of Investor Relationsno datano datano data
Brandon Owens
VP of Strategic Marketing & Corporate Communicationno datano datano data
Margaret Galluzzi
VP & Global Head of Clinical Operations5.9yrsno datano data
Leonard Farber
Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board2.8yrsno datano data

5.4yrs

Average Tenure

51yo

Average Age

Experienced Management: NANO's management team is seasoned and experienced (5.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Leonard Farber
Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Boardno datano datano data
Enno Spillner
Independent Member of Supervisory Board10.5yrs€50.00kno data
Gary Phillips
Independent Chairman of Supervisory board3.6yrs€63.00kno data
Silvia Formenti
Member of Scientific Advisory Board2.1yrsno datano data
Alain Herrera
Independent Member of Supervisory Board11.5yrs€35.00kno data
Anne-Marie Graffin
Independent Vice Chairman of the Supervisory Board11yrs€42.00kno data
Hisham Mehanna
Member of Scientific Advisory Board2.1yrsno datano data
Stephane Champiat
Member of Scientific Advisory Board2.1yrsno datano data
Jean Bourhis
Member of Scientific Advisory Board2.1yrsno datano data
Thierry Baere
Member of Scientific Advisory Board2.1yrsno datano data
Christophe Tourneau
Member of Scientific Advisory Board2.1yrsno datano data
Nancy Lee
Member of Scientific Advisory Board2.1yrsno datano data

2.1yrs

Average Tenure

60.5yo

Average Age

Experienced Board: NANO's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 05:46
End of Day Share Price 2024/12/30 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nanobiotix S.A. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mickael Chane-DuBryan Garnier & Co
Philippa GardnerEdison Investment Research
Jonathan MillerEvercore ISI